View in EDS

Primary Endpoint Analysis of the Phase 2 DESTINATION-MRL Trial for Patients With Intermediate-Risk Prostate Cancer.

Saved in:
Bibliographic Details
Title: Primary Endpoint Analysis of the Phase 2 DESTINATION-MRL Trial for Patients With Intermediate-Risk Prostate Cancer.
Authors: Dassen MG; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Tree AC; Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom., Wiersema L; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Neijndorff B; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Ruiter P; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Linden J; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Mitchell A; Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom., Dunlop A; Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom., Alexander S; Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom., Breitkreutz DY; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada., Cooper S; Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom., Janssen T; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Pos F; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Vesprini D; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada., van der Heide UA; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: u.vd.heide@nki.nl.
Source: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2026 May 01; Vol. 125 (1), pp. 257-265. Date of Electronic Publication: 2025 Nov 26.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 7603616 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-355X (Electronic) Linking ISSN: 03603016 NLM ISO Abbreviation: Int J Radiat Oncol Biol Phys Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-355X
DOI:10.1016/j.ijrobp.2025.11.028